Denmark

How Have HTA Agencies Evolved Their Methods Over Time?

29 April 2024

The many changes in Health Technology Assessment (HTA) methods and processes over time, are a challenge to navigate let alone stay abreast of. This report explores the breadth of variation in past and current positioning of HTA agencies in 14 countries, on five key methodological topics: discount rates, modifiers, patient involvement, real-world evidence (RWE), and surrogate endpoints.

Are Recommendations for HTA of Gene Therapies Being Achieved?

11 September 2023

In this report, commissioned and funded by Pfizer, we explore the extent to which previous OHE recommendations for the health technology assessment (HTA) of gene therapies are being achieved in nine European countries, Australia, and Canada.

Learnings from the Assessments of Entrectinib and Larotrectinib: Health Technology Assessment Challenges Associated with Tumour-Agnostic Therapies

1 January 2022

A paradigm shift is occurring in cancer care with the introduction of tumour-agnostic therapies, for which the indication is defined by the molecular signature of the…